Trials / Recruiting
RecruitingNCT05051436
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 96 (estimated)
- Sponsor
- Philip Kern · Academic / Other
- Sex
- All
- Age
- 35 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The investigator hypothesizes that treatment with the ß3 agonist mirabegron results in improved glucose metabolism, including a reversal of prediabetes in obese, insulin-resistant human research participants, and this is further improved by combination therapy with tadalafil. The investigator will comprehensively analyze glucose homeostasis in prediabetic patients treated for 14 weeks with mirabegron, tadalafil or both drugs as compared to a placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mirabegron 50 MG | Mirabegron 50 mg/day will be administered for 14 weeks. |
| DRUG | Tadalafil 10 MG | Tadalafil 10 mg/day will be administered for 14 weeks after baseline procedures. |
| DRUG | Placebo | Placebo will be administered for 14 weeks after baseline procedures. |
Timeline
- Start date
- 2021-12-13
- Primary completion
- 2026-08-01
- Completion
- 2026-08-01
- First posted
- 2021-09-21
- Last updated
- 2026-02-03
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05051436. Inclusion in this directory is not an endorsement.